Zhitong Finance App News, Cinda Biotech (01801.HK) announced that the company's seven innovative products were successfully included in the new “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2025)”, including: Dabershu® (cindilizumab injection, anti-PD-1 monoclonal antibody), new indications, Xinbimin® (tetuumab N01 injection, anti-IGF-1R monoclonal antibody), Aoyixin® (liotinib tablets, EGFR TKI), and Flubert® (Flubert®) Zereside tablets, KRAS G12C inhibitors), Dabol ® (tarretinib adipate capsules, ROS1TKI), Ruituo® (ceptinib capsules, RET inhibitor), dapalil® (pitobutinib tablets, BTK inhibitors). The new version of the National Medical Insurance Drug Catalogue will be officially implemented on January 1, 2026.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Cinda Biotech (01801.HK) announced that the company's seven innovative products were successfully included in the new “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2025)”, including: Dabershu® (cindilizumab injection, anti-PD-1 monoclonal antibody), new indications, Xinbimin® (tetuumab N01 injection, anti-IGF-1R monoclonal antibody), Aoyixin® (liotinib tablets, EGFR TKI), and Flubert® (Flubert®) Zereside tablets, KRAS G12C inhibitors), Dabol ® (tarretinib adipate capsules, ROS1TKI), Ruituo® (ceptinib capsules, RET inhibitor), dapalil® (pitobutinib tablets, BTK inhibitors). The new version of the National Medical Insurance Drug Catalogue will be officially implemented on January 1, 2026.